Skip to main content

Table 3 Adjusted logistic regression model for non-adherence (medication possession ratio (MPR) < 0.80)*

From: Adherence with urate-lowering therapies for the treatment of gout

Variable† Adjusted odds ratio (95% confidence interval)
Sociodemographic:  
Gender, female 1.03 (0.88 to 1.19)
Age  
   <45 2.43 (1.86 to 3.18)
   45 to 49 1.45 (1.08 to 1.93)
   50 to 54 1.09 (0.86 to 1.39)
   55 to 59 0.78 (0.61 to 0.99)
   60 to 64 0.75 (0.59 to 0.96)
   65 to 69 0.84 (0.67 to 1.04)
   70 to 74 0.83 (0.67 to 1.02)
   75 + 1.00
Health status:  
Charlson comorbidity score  
   0 1.46 (1.20 to 1.77)
   1 1.21 (0.98 to 1.51)
   2 1.20 (0.94 to 1.53)
   3 or more 1.00
Gout care:  
Number of provider visits for gout prior to ULD initiation  
   0 1.28 (1.05 to 1.55)
   1 1.09 (0.92 to 1.30)
   2 1.00 (0.83 to 1.21)
   3 or more 1.00
Use of acute gout meds 1 to 12 months prior to urate-lowering drug initiation  
   NSAIDs 1.15 (1.00 to 1.31)
  1. *A backward elimination method was used retaining all variables considered to be potentially important. Variables with P values < 0.10 remained in the final models. The Hosmer-Lemeshow goodness of fit had a P value of 0.70; †model after controlling for health plan.
  2. NSAID, non-steroidal anti-inflammatory drug; ULD, urate-lowering drug.